

Monica Casucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9336405/publications.pdf>

Version: 2024-02-01

24
papers

2,596
citations

566801

15
h-index

713013

21
g-index

24
all docs

24
docs citations

24
times ranked

4411
citing authors

#	ARTICLE	IF	CITATIONS
1	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. <i>Nature Medicine</i> , 2018, 24, 739-748.	15.2	947
2	Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2009, 361, 478-488.	13.9	459
3	CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. <i>Blood</i> , 2013, 122, 3461-3472.	0.6	306
4	Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. <i>Nature Immunology</i> , 2020, 21, 1552-1562.	7.0	167
5	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. <i>Nature Communications</i> , 2019, 10, 1065.	5.8	120
6	Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene. <i>Frontiers in Immunology</i> , 2018, 9, 507.	2.2	73
7	NY-ESO-1 TCR single edited stem and central memory T cells to treat multiple myeloma without graft-versus-host disease. <i>Blood</i> , 2017, 130, 606-618.	0.6	71
8	Next-Generation Manufacturing Protocols Enriching TSCM CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1217.	2.2	69
9	CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	66
10	Overcoming the toxicity hurdles of genetically targeted T cells. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 123-130.	2.0	51
11	Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T Lymphocytes. <i>Journal of Cancer</i> , 2011, 2, 378-382.	1.2	47
12	Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. <i>Science Translational Medicine</i> , 2022, 14, eabg3072.	5.8	47
13	Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. <i>Immunological Reviews</i> , 2014, 257, 165-180.	2.8	46
14	Graft-versus-leukemia Effect of HLA-haploidentical Central-memory T-cells Expanded With Leukemic APCs and Modified With a Suicide Gene. <i>Molecular Therapy</i> , 2013, 21, 466-475.	3.7	23
15	Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. , 2022, 10, e003486.		21
16	Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies. <i>Human Gene Therapy</i> , 2017, 28, 231-241.	1.4	19
17	Exploiting Secreted Luciferases to Monitor Tumor Progression In Vivo. <i>Methods in Molecular Biology</i> , 2016, 1393, 105-111.	0.4	13
18	Myeloid cell-based delivery of IFN α 3 reprograms the leukemia microenvironment and induces anti-tumoral immune responses. <i>EMBO Molecular Medicine</i> , 2021, 13, e13598.	3.3	13

#	ARTICLE	IF	CITATIONS
19	Time 2EVOLVE: predicting efficacy of engineered T-cells “ how far is the bench from the bedside?. , 2022, 10, e003487.		13
20	Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer. Human Gene Therapy, 2021, 32, 744-760.	1.4	10
21	Overcoming key challenges in cancer immunotherapy with engineered T cells. Current Opinion in Oncology, 2020, 32, 398-407.	1.1	9
22	Human T cells engineered with a leukemia lipid-specific TCR enables donor-unrestricted recognition of CD1c-expressing leukemia. Nature Communications, 2021, 12, 4844.	5.8	3
23	Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication. Blood, 2012, 120, 949-949.	0.6	3
24	102â€¦The deep phenotype characterization of “Off-the-Shelf”™ CD19-chimeric antigen receptor (CAR) T cells allows to identify their subset complexity and to optimize their manufacturing. , 2021, 9, A111-A112.		0